Adv. Ido Zemach’s broad-based transactional practice concentrates on M&As, capital markets transactions and corporate governance matters, and he has been involved in numerous high-profile and complex international transactions, including struggles for corporate control and shareholder activism, valued at a total of over $100 billion.
Ido advises emerging companies as well as public companies, committees of independent directors, investment banks, PE and VC funds, on a broad array of corporate and securities law matters as well as domestic and cross-border transactions, including M&As; public offerings; investments; technology licensing; and franchise transactions in a variety of industries, including TMT, life sciences, cyber, gaming, infrastructure and energy, aviation, food and retail, spreading over diverse geographies, including the U.S., Europe, China, India and Japan.
Ido acted in the past few years in a number of significant corporate transactions involving the representation of a range of domestic and foreign companies, including Attunity (Nasdaq: ATTU) on its sale to Qlik (a Thoma Bravo company); Google on its acquisition of Waze; Intel on its acquisitions of Replay Video and Sentrigo; Itamar Medical (Nasdaq: ITMR) on its Nasdaq IPO and sale to ZOLL Medical; J.P. Morgan, Barclays, Jefferies and the other underwriters on the IPO of Tufin Software (Nasdaq: TUFN); Micron (Nasdaq: MU) on its acquisition of Numonyx and the sale of Israeli plant to Intel; Mitsubishi Tanabe Pharma on its acquisition of NeuroDerm (Nasdaq: NDRM); Ormat Industries (TASE: ORMT) on its reorganization with Ormat Technologies (NYSE: ORA); Radware (Nasdaq: RDWR) on several acquisitions; Signet Jewelers (NYSE: SIG) on its acquisition of R2Net; TCV on its investment in Payoneer; Mivne Group on its data centers JV with DLR; Kryon Systems on its sale to Nintex; Trustodome on its sale to Zscaler (Nasdaq: ZS); IBF on its PIPE investment in MediWound (Nasdaq: MDWD); Smith & Nephew (NYSE: SNN) on its acquisition of CartiHeal; and Bynet Data Centers on its financing from Noy Fund.
Ido routinely advises boards of directors and management teams on their most sensitive and crucial matters, devising creative solutions to achieve their goals, including the structuring of the first U.S. style shareholder rights plan (a/k/a ‘poison pill’) ever adopted by an Israeli company and the first special tender offer conducted for a dual listed company.
Ido was recognized as a leading M&A and capital markets attorney by a number of international guides and occasionally publishes professional articles and lectures on different aspects of his practice areas at academic and professional forums.
Following law school, Ido clerked for the Tel Aviv District Attorney (Fiscal Department). From 1999 to 2000, he was an associate at the corporate department of Wachtell, Lipton, Rosen & Katz, New York.
LL.M., Banking, Corporate and Finance Law, Fordham University, New York, 1999
LL.B., Hebrew University of Jerusalem, 1996
Israel Bar Association, 1997
New York Bar Association, 2000
